Óscar Fernández1, Gavin Giovannoni2, Robert J Fox3, Ralf Gold4, J Theodore Phillips5, James Potts6, Macaulay Okwuokenye7, Jing L Marantz6. 1. Department of Neurology, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario, Málaga University, Málaga, Spain. 2. Blizard Institute, Queen Mary University of London, London, United Kingdom. 3. Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio. 4. St. Josef Hospital, Ruhr University Bochum, Bochum, Germany. 5. Multiple Sclerosis Program, Baylor Institute for Immunology Research, Dallas, Texas, USA. 6. Biogen, Cambridge, Massachusetts, USA. 7. Biogen, Cambridge, Massachusetts, USA. Electronic address: macaulay.okwuokenye@biogen.com.
Abstract
PURPOSE: In Phase III studies (DEFINE [Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting MS]/CONFIRM [Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis]), delayed-release dimethyl fumarate (DMF) demonstrated significant efficacy and a favorable benefit-risk profile in patients with relapsing-remitting multiple sclerosis (RRMS). Post hoc analyses of integrated data from DEFINE/CONFIRM were conducted to evaluate the effect of DMF in patients previously treated with interferon (IFN) beta. METHODS:Patients (age 18-55 years; Expanded Disability Status Scale score, 0-5.0) were randomized to receive DMF 240 mg BID or TID, placebo, or glatiramer acetate (CONFIRM only) for up to 2 years. Previous IFN users received at least 1 IFN treatment >3 months before randomization. Data for DMF 240 mg BID (approved dosing regimen) are reported. FINDINGS: In the integrated intention-to-treat population, 172 and 169 patients receivingDMF or placebo, respectively, had received ≥1 prior IFN. In this subgroup, significant reductions with DMF versus placebo were observed for the annualized relapse rate (rate ratio, 0.55 [95% CI, 0.40-0.77]), new/newly enlarging T2-hyperintense lesions (lesion mean ratio, 0.16 [95% CI, 0.09-0.29]), odds of having more gadolinium-enhancing lesions (odds ratio, 0.17 [95% CI, 0.07-0.44]), and new T1-hypointense lesions (lesion mean ratio, 0.25 [95% CI, 0.14-0.45]). Median Expanded Disability Status Scale scores remained stable during the study period. Adverse events associated with DMF included flushing and gastrointestinal events. IMPLICATIONS: In this post hoc analysis in patients with previous IFN treatment, DMF demonstrated significant efficacy over 2 years versus placebo and an adverse event profile consistent with the overall population of DEFINE/CONFIRM. ClinicalTrials.gov identifiers: DEFINE, NCT00420212; and CONFIRM, NCT00451451.
RCT Entities:
PURPOSE: In Phase III studies (DEFINE [Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting MS]/CONFIRM [Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis]), delayed-release dimethyl fumarate (DMF) demonstrated significant efficacy and a favorable benefit-risk profile in patients with relapsing-remitting multiple sclerosis (RRMS). Post hoc analyses of integrated data from DEFINE/CONFIRM were conducted to evaluate the effect of DMF in patients previously treated with interferon (IFN) beta. METHODS:Patients (age 18-55 years; Expanded Disability Status Scale score, 0-5.0) were randomized to receive DMF 240 mg BID or TID, placebo, or glatiramer acetate (CONFIRM only) for up to 2 years. Previous IFN users received at least 1 IFN treatment >3 months before randomization. Data for DMF 240 mg BID (approved dosing regimen) are reported. FINDINGS: In the integrated intention-to-treat population, 172 and 169 patients receiving DMF or placebo, respectively, had received ≥1 prior IFN. In this subgroup, significant reductions with DMF versus placebo were observed for the annualized relapse rate (rate ratio, 0.55 [95% CI, 0.40-0.77]), new/newly enlarging T2-hyperintense lesions (lesion mean ratio, 0.16 [95% CI, 0.09-0.29]), odds of having more gadolinium-enhancing lesions (odds ratio, 0.17 [95% CI, 0.07-0.44]), and new T1-hypointense lesions (lesion mean ratio, 0.25 [95% CI, 0.14-0.45]). Median Expanded Disability Status Scale scores remained stable during the study period. Adverse events associated with DMF included flushing and gastrointestinal events. IMPLICATIONS: In this post hoc analysis in patients with previous IFN treatment, DMF demonstrated significant efficacy over 2 years versus placebo and an adverse event profile consistent with the overall population of DEFINE/CONFIRM. ClinicalTrials.gov identifiers: DEFINE, NCT00420212; and CONFIRM, NCT00451451.
Authors: Giulia Mallucci; P Annovazzi; S Miante; V Torri-Clerici; M Matta; S La Gioia; R Cavarretta; V Mantero; G Costantini; V D'Ambrosio; M Zaffaroni; A Ghezzi; P Perini; S Rossi; A Bertolotto; M R Rottoli; M Rovaris; R Balgera; P Cavalla; C Montomoli; R Bergamaschi Journal: J Neurol Date: 2018-06-14 Impact factor: 4.849
Authors: Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve Journal: Front Immunol Date: 2019-07-11 Impact factor: 7.561
Authors: Kristen S Hill; Anthony McDowell; J Robert McCorkle; Erin Schuler; Sally R Ellingson; Rina Plattner; Jill M Kolesar Journal: Cancers (Basel) Date: 2021-04-14 Impact factor: 6.639
Authors: Minna Oksanen; Ida Hyötyläinen; Kalevi Trontti; Taisia Rolova; Sara Wojciechowski; Marja Koskuvi; Matti Viitanen; Anna-Liisa Levonen; Iiris Hovatta; Laurent Roybon; Šárka Lehtonen; Katja M Kanninen; Riikka H Hämäläinen; Jari Koistinaho Journal: Glia Date: 2019-10-31 Impact factor: 7.452